CVSG.L | Ticker Profile - Titan Protect

CVSG.L

CVS Group plc

Healthcare · Medical Care Facilities · LSE

$1,234.00

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$870M

Total market value of the company

Trailing P/E

53.91

Expensive — high growth expected

Forward P/E

13.06

Based on estimated future earnings — lower means cheaper

Rev Growth

+5.8%

Year-over-year revenue change

Profit Margin

7.1%

How much profit the company keeps from each dollar of revenue

ROE

6.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$1,600.00

+30% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 10 analysts covering this stock

About CVS Group plc

CVS Group plc, together with its subsidiaries, engages in veterinary, online pharmacy, and retail businesses in the United Kingdom and Australia. It operates through the Veterinary Practices, Laboratories, and Online Retail Business segments. The company is involved in animal veterinary practices and complementary veterinary diagnostic businesses. It also operates Animed Direct, an online retail business that sells prescription and non-prescription medicines, pet foods, and other pet care products, as well as an online dispensary. In addition, the company provides veterinary instrumentation supply and property development services. The company was founded in 1999 and is headquartered in Diss, the United Kingdom.

https://www.cvsukltd.co.uk

Country: United Kingdom Employees: 9,000 Industry: Medical Care Facilities

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.383

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0006

No positive edge detected — the data suggests staying out

Calmar Ratio

0.228

Drawdown risk outweighs the returns — higher risk profile

Annual Return

7.6%

Historical annualised return based on price data

Max Drawdown

-33.3%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

160

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.02

Moves slightly more than the broader market

52W High

$1,648.00

25% below the year high

52W Low

$1,062.00

16% above the year low

Avg Volume

378,976

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

69.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$0.23

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

90.86

Heavy leverage — higher financial risk if revenues decline

Current Ratio

1.07

Adequate but worth monitoring

Quick Ratio

0.81

Like current ratio but excludes inventory — stricter test

Gross Margin

43.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

6.2%

Profit from core operations before interest and tax

Free Cash Flow

$52M

Positive — the business generates more cash than it spends

Revenue (TTM)

$693M

Total revenue over the last 12 months

Net Income

$17M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$2,000.00

Target Median

$1,600.00

Target Low

$1,340.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go